Categories: News

Genalyte Announces Oversubscribed $50 Million Financing Round to Expand Testing Menu and Deploy Platform

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ — Genalyte, a leading diagnostics and analytics company, announced today the closure of $50 million in financing.  Genalyte’s Maverick™ Diagnostic System (MDS) uses silicon chip based photonic ring resonance technology to perform multiple, simultaneous, rapid tests on a small volume of whole blood or serum in twenty minutes.

“We are energized by the very enthusiastic response from Investors for this latest round of funding,” said CEO Ashraf Hanna.  “Genalyte is uniquely positioned to improve the laboratory diagnostic and analytic space.  We’ve demonstrated the strength of our technology in our EUA authorized SARS-CoV-2 Multi-Antigen Serology Panel, which is able to measure 26 different antibodies from one drop of blood.  Independent tests by the Mayo Clinic, Scripps, and Northshore Healthcare have consistently verified the platform’s industry leading capabilities.”  

The financing round was led by Verily, an Alphabet company, and included current major investors Provenio Capital, Redmile, Khosla Ventures, HBM Partners, Samsara and others.

Andy Conrad, CEO and founder of Verily has been nominated to Genalyte’s board of directors.  “Verily and Genalyte share a common vision of empowering physicians and patients with timely insights to improve outcomes and lower the cost of care,” said Andrew Conrad.  “I look forward to working with Genalyte as they continue to innovate technology to advance rapid diagnostics and analytics.”

The company intends to utilize the funding to expand the Maverick test menu and rapidly deploy the Maverick platform in clinical and retail settings.  

About Genalyte: Genalyte is a healthcare diagnostics and analytics company that improves patient outcomes and lowers cost with real-time results for physicians and patients. Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing. For more information, please visit www.genalyte.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genalyte-announces-oversubscribed-50-million-financing-round-to-expand-testing-menu-and-deploy-platform-301205549.html

SOURCE Genalyte Inc

Staff

Recent Posts

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

5 hours ago

MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"),…

7 hours ago

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) is pleased to announce…

7 hours ago

ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona

SAN DIEGO, Dec. 12, 2025 /PRNewswire/ -- ISHI Health, an innovator in AI-enabled virtual cardiac…

7 hours ago

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight…

7 hours ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…

7 hours ago